Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review

The development of intravitreally injected biologic medicines (biologics) acting against vascular endothelial growth factor (VEGF) substantially improved the clinical outcomes of patients with common VEGF-driven retinal diseases. The relatively high cost of branded agents, however, represents a financial burden for most healthcare systems and patients, likely resulting in impaired access to treatment and poorer clinical outcomes for some patients. Biosimilar medicines (biosimilars) are clinically equivalent, potentially economic alternatives to reference products.

Source: Survey of Ophthalmology - March 21, 2024 Category: Opthalmology Authors: Neil M Bressler, Peter K Kaiser, Diana V Do, Quan Dong Nguyen, Kyu Hyung Park, Se Joon Woo, Min Sagong, Mario Bradvica, Mercy Yeeun Kim, Seungkee Kim, SriniVas R Sadda Tags: Review article Source Type: research